Last reviewed 2026-05-28 · How we verify

Viviant

Pfizer · Phase 2 active Small molecule ✓ Verified May 2026

Viviant is a Small molecule drug developed by Pfizer. It is currently in Phase 2 development.

Viviant, also known as conjugated estrogens/bazedoxifene (CE/BZA), is a medication used to treat postmenopause, menopause, prediabetes, obesity, and osteoporosis. It is a combination of conjugated estrogens and bazedoxifene, which is an estrogen receptor modulator.

Likelihood of approval

18.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
Pfizer is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Viviant
Sponsor	Pfizer
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers (EARLY_PHASE1)
Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens (PHASE2)
Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis (PHASE2)
Raising Insulin Sensitivity in Post Menopause (EARLY_PHASE1)
The PROMISE Study: Duavee in Women With DCIS (PHASE2)
Advancing Postmenopausal Preventive Therapy (PHASE2)
Affect of Duavive on Mood & Anxiety Symptoms (PHASE1)
Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Viviant CI brief — competitive landscape report
Viviant updates RSS · CI watch RSS
Pfizer portfolio CI

Frequently asked questions about Viviant

What is Viviant?

Viviant is a Small molecule drug developed by Pfizer.

Who makes Viviant?

Viviant is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What development phase is Viviant in?

Viviant is in Phase 2.

Manufacturer: Pfizer — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing